LDL-cholesterol levels in patients with coronary heart disease receiving lipid-lowering therapy: Relation to pretreatment LDL-cholesterol and CHD risk status (reality study, Germany)

被引：0
|
作者：
Krobot, KJ
Yin, D
Alemao, E
Steinhagen-Thiessen, E
机构：
[1] MSD Sharp & Dohme GMBH, Haar, Germany
[2] Humboldt Univ, Charite, Berlin, Germany
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2004年 / 5卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
下载
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [31] Plasma lipoprotein (a) levels and LDL-cholesterol lowering response to statin therapy in patients with heterozygous familial hypercholesterolaemia
    Miltiadous, G.
    Cariolou, M.
    Mitrogianni, Z. O. I.
    Doumas, M.
    Saougkos, V.
    Bairaktari, E.
    Elisaf, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 530 - 530
  • [32] Triglyceride levels predict coronary artery disease prevalence only in patients with low ldl-cholesterol
    Wanitschek, M.
    Suessenbacher, A.
    Doerler, J.
    Pachinger, O.
    Ulmer, H.
    Alber, H. F.
    EUROPEAN HEART JOURNAL, 2010, 31 : 646 - 647
  • [33] Correlation between pretreatment serum LDL-cholesterol levels and prognosis in nasopharyngeal carcinoma patients
    Tang, Qiu
    Hu, Qiao-Ying
    Piao, Yong-Feng
    Hua, Yong-Hong
    ONCOTARGETS AND THERAPY, 2016, 9 : 2585 - 2591
  • [34] Antisense agent reduces LDL-cholesterol levels in high-risk patients
    不详
    NATURE REVIEWS DRUG DISCOVERY, 2010, 9 (01) : 10 - 10
  • [35] Reasons Why Combination Therapy Should Be the New Standard of Care to Achieve the LDL-Cholesterol Targets: Lipid-lowering combination therapy
    Masana, Lluis
    Ibarretxe, Daiana
    Plana, Nuria
    CURRENT CARDIOLOGY REPORTS, 2020, 22 (08)
  • [36] Practice patterns for addressing LDL-cholesterol levels below 40 in patients receiving statin therapy.
    Helsing, Haleigh
    Taylor, Perry
    Dixon, Dave
    PHARMACOTHERAPY, 2017, 37 (06): : E40 - E41
  • [37] LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy
    Hamasaki, Masato
    Sakane, Naoki
    Hara, Kazuo
    Kotani, Kazuhiko
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2021, 35 (11)
  • [38] Long-term moderately elevated LDL-cholesterol and blood pressure and risk of coronary heart disease
    Ueda, Peter
    Gulayin, Pablo
    Danaei, Goodarz
    PLOS ONE, 2018, 13 (07):
  • [39] Impact of a virtual lipid clinic on lipid-lowering therapy, LDL cholesterol levels, and outcomes in patients with acute coronary syndrome
    Garcia, Rafael Vazquez
    Garcia, Juan Enrique Puche
    Navas, William Delgado
    Salmeron, Diego Mialdea
    Mateos, Daniel Bartolome
    JOURNAL OF CLINICAL LIPIDOLOGY, 2022, 16 (05) : 635 - 642
  • [40] Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization
    Farkouh, Michael E.
    Godoy, Lucas C.
    Brooks, Maria M.
    Mancini, G. B. John
    Vlachos, Helen
    Bittner, Vera A.
    Chaitman, Bernard R.
    Siami, Flora S.
    Hartigan, Pamela M.
    Frye, Robert L.
    Boden, William E.
    Fuster, Valentin
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (19) : 2197 - 2207
12345